期刊文献+

他汀对血脂正常者的心血管事件预防作用 被引量:5

The prophylactic effects of statins on cardiovascular events in patients with normal level of plasma lipids
下载PDF
导出
摘要 冠心病一、二级预防研究显示 ,低密度脂蛋白胆固醇低于血脂指南治疗水平甚至正常者 ,他汀也能明显降低心血管危险性。其原因是 :指南中的“正常”水平并非生物学正常水平 ,仅是某人群的平均值 ;血脂成分是非常复杂的 ;他汀具有调脂外作用。 Primary and secondary prevention clinical trials have demonstrated that statins markedly reduced cardiovascular risks even in patients whose plasma level of low-density lipoprotein cholesterol is lower than that of drug-treatment goal in lipid management guidelines. The reasons are as follows: The 'normal' level in guidelines is not the normal level biologically, it is merely an average value in a given human group; The composition of plasma lipids is very complex; Statins have effects other than lipid modifying. Statins should be prescribed in patients without hyperlipidemia but with risk factors or coronary heart disease.
出处 《中国药理学通报》 CAS CSCD 北大核心 2003年第11期1208-1211,共4页 Chinese Pharmacological Bulletin
关键词 他汀 冠心病 低密度脂蛋白胆固醇 血脂 statin coronary heart disease LDL-C lipid
  • 相关文献

参考文献17

  • 1方圻,王钟林,宁田海,邵耕,陈在嘉,陆宗良,李健斋,林传骧,周北凡,诸骏仁,诸永康,陶萍,陶寿淇,龚兰生,顾复生,游凯,戴玉华.血脂异常防治建议[J].中华心血管病杂志,1997,25(3):169-175. 被引量:3067
  • 2Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S).Lancet, 1994;344(8934) : 1383-9.
  • 3Sacks Fm, Pfeffer MA, Moye LA et al . For the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996 ;335(14) :1001-9.
  • 4The post-coronary artery bypass graft trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med, 1997 ;336(3) : 153-62.
  • 5The long-term intervention with pravastatin in ischaemic disease(LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med,1998 ;339(19) :1349-57.
  • 6Downs JR, Clearfield M, Weis S et al. For the AFCAPS/Tex-CAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 1998; 279(20):1615-22.
  • 7Schwartz GG, Olsson AG, Ezekowitz MD et al. For the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in patients with acute coronary syndromes: The MIRICL study -a randomized controlled trial.JAMA,2001;285(13):1711-8.
  • 8Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals:A randomisedplacebcr-controlledtrial. Lancet,2002;360(9326) :7-22.
  • 9Branchi A, Fiorenza AN, Rovellini A et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol,1999;55(7):499-502.
  • 10The expert panel: Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel Ⅲ). JAMA, 2001;285(19) : 2486-97.

共引文献3066

同被引文献29

  • 1赵水平.降低低密度脂蛋白胆固醇在冠心病防治中的重要性[J].中华全科医师杂志,2005,4(2):72-74. 被引量:18
  • 2钱颖,范春雷,窦晓兵,胡林峰,沃兴德.姜黄素对293细胞固醇调控报告系统的作用[J].中国药理学通报,2006,22(7):828-830. 被引量:11
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 4Mas R,Cas T G,Fer N D J,et al. Long-term effects of policosanol on obese patients with Type Ⅱ Hypercholesterolemia[ J]. Asia Pac J Clin Nutr,2004,13 (Suppl) :S102.
  • 5Mirkin A, Mas R, Mar T M,et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women[ J ]. Int J Clin Pharmacol Res ,2001,21 (1) :31 -41.
  • 6Castano G, Mas R, For nandez L,et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly prtients with type Ⅱ hypercholesterolaemia [ J ]. Drugs Aging, 2003,20 (2) :153 - 63.
  • 7Dev K S, Li L, Porter T D. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase[ J]. J Pharmacol Exp Therap Fast Forw,2006 ,DOI: 10. 1124/jpet. 106. 107144.
  • 8McCarty M F. Policosanol safely down-regulates HMG-CoA reductase-potential as a component of the Esselstyn regimen [ J ]. Med Hypotheses ,2002,59 ( 3 ) : 268 - 79.
  • 9Stephan Z F, Yurachek E C. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL[ J]. J Lipid Research, 1993,34 (2) :325 -30.
  • 10Cuthbert J A, Russell D W, Lipsky P E. Regulation of low density lipoprotein receptor gene expression in human lymphocytes [ J ]. Biol Chem, 1989,264 : 1298 - 303.

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部